Feb 12 (Reuters) - Drugmaker Takeda said on Monday the U.S. Food and Drug Administration has approved its therapy for a type of allergic inflammation of the esophagus, making it the first oral treatment for the condition. (Reporting by Sriparna Roy in Bengaluru; Editing by Krishna Chandra Eluri)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4,070 JPY | +0.42% | -1.76% | +0.39% |
03:21pm | Sector Update: Health Care Stocks Steady Pre-Bell Thursday | MT |
10:33am | Takeda Pharmaceutical's Fiscal Q1 Core Earnings Decline, Revenue Increases; Fiscal 2024 Outlook Issued | MT |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
4,070 JPY | +0.42% | -1.76% | 40.87B | ||
2,713 PTS | +0.26% | -0.58% | - | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.39% | 40.87B | |
+32.67% | 698B | |
+26.51% | 568B | |
-4.54% | 358B | |
+19.62% | 328B | |
+3.46% | 283B | |
+16.34% | 238B | |
+6.68% | 203B | |
-9.08% | 198B | |
+8.94% | 165B |
- Stock Market
- Equities
- 4502 Stock
- News Takeda Pharmaceutical Company Limited
- US FDA approves Takeda's therapy for allergic inflammation in esophagus